Recursion Pharmaceuticals Reports Grant of Inducement Awards as Permitted by the Nasdaq Listing Rules
20. Dezember 2024 16:05 ET
|
Recursion Pharmaceuticals
Salt Lake City, Utah, Dec. 20, 2024 (GLOBE NEWSWIRE) -- Recursion Pharmaceuticals, Inc. (“Recursion”) (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug...
Recursion and Exscientia Shareholders Approve the Proposed Combination
13. November 2024 09:08 ET
|
Recursion Pharmaceuticals
Salt Lake City USA, Oxford UK, Nov. 13, 2024 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX) and Exscientia plc (Nasdaq: EXAI) have each received overwhelming approval from their shareholders for the...
Recursion Provides Business Updates and Reports Third Quarter 2024 Financial Results
06. November 2024 16:15 ET
|
Recursion Pharmaceuticals
Multiple clinical trial milestones were achieved, including encouraging topline data for a Phase 2 trial in CCM, the first patient dosed for a Phase 2 trial in recurrent C. difficile infection, and...
Recursion to Report Third Quarter 2024 Business Updates and Financial Results on November 6th
30. Oktober 2024 08:22 ET
|
Recursion Pharmaceuticals
Salt Lake City, UT, Oct. 30, 2024 (GLOBE NEWSWIRE) -- Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, announced today it will...
CORRECTION - Recursion Provides Business Updates and Reports Second Quarter 2024 Financial Results
08. August 2024 14:41 ET
|
Recursion Pharmaceuticals
SALT LAKE CITY, Aug. 08, 2024 (GLOBE NEWSWIRE) -- In a release issued under the same headline earlier today by Recursion (Nasdaq: RXRX), please note that in the first bullet under "Additional...
Recursion Provides Business Updates and Reports Second Quarter 2024 Financial Results
08. August 2024 07:30 ET
|
Recursion Pharmaceuticals
Recursion entered into a definitive agreement to combine with Exscientia to add its technology-enabled clinical pipeline, sector-leading partnerships, and precision chemistry capabilitiesRecursion...
Recursion updates L(earnings) call on August 8th to 8:30 am ET / 6:30 am MT
08. August 2024 01:32 ET
|
Recursion Pharmaceuticals
Salt Lake City, Aug. 08, 2024 (GLOBE NEWSWIRE) -- Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, will provide business updates...
Recursion to Report Second Quarter 2024 Business Updates and Financial Results on August 8th
05. August 2024 16:01 ET
|
Recursion Pharmaceuticals
Salt Lake City, Aug. 05, 2024 (GLOBE NEWSWIRE) -- Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, announced today it will provide...
Recursion Announces Pricing of $200 Million Public Offering of Class A Common Stock
26. Juni 2024 22:07 ET
|
Recursion Pharmaceuticals
Salt Lake City, June 26, 2024 (GLOBE NEWSWIRE) -- Recursion Pharmaceuticals, Inc. (“Recursion”) (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug...
Recursion Announces Proposed Offering of Class A Common Stock
26. Juni 2024 16:06 ET
|
Recursion Pharmaceuticals
Salt Lake City, June 26, 2024 (GLOBE NEWSWIRE) -- Recursion Pharmaceuticals, Inc. (“Recursion”) (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug...